3.9 Article

An Update on the Use of Orthobiologics: Use of Biologics for Osteoarthritis

期刊

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.otsm.2020.150759

关键词

biologic; osteoarthritis; knee; hip

向作者/读者索取更多资源

Osteoarthritis is a highly prevalent joint disorder affecting over 30 million adults in the United States. This debilitating disorder is associated with pain and decreased physical function. Though total joint arthroplasty is generally successful, this procedure has associated risk and many patients still have residual pain. Nonoperative treatments have been investigated to provide patients with durable pain relief with lower levels of associated risks. Orthobiologics, such as platelet-rich plasma, bone marrow aspirate concentrate, and amniotic products, contain cytokines and/or mesenchymal progenitor cells that have been demonstrated to modulate the pathogenesis of osteoarthritis in animal and basic science models and may provide clinical improvement in the clinical setting. This chapter will cover recent clinical trials involving orthobiologic injections in patients with hip or knee osteoarthritis. (c) 2020 Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据